ARL11 and cancer: Overall, when the 11 studies were pooled into the meta-analysis, the significant main effects on cancer risk were associated with ARLTS1 Cys148Arg (CC vs. TT: 1.27 (1.15–1.41), p = 0.000 Fig. 2; CC + TC vs. TT: 1.13 (1.02–1.27), p = 0.026 Fig. 3; CC vs. TC + TT: 1.16 (1.00–1.35), p = 0.045).